What BioCopy does

BioCopy is a German-Swiss pre-clinical biotechnology company that develops biotherapeutics against cancer using an AI-powered, end-to-end automated drug discovery platform. The company is advancing five pHLA-targeted antibody programs across solid and liquid tumors, with the stated goal of delivering multiple clinical candidates within the next 3-4 years. BioCopy is incorporated as BioCopy AG in Basel, Switzerland, with operating roots in Freiburg, Germany, and runs a small team of 1-10 employees.

The company's core technology stack combines three proprietary elements: ValidaTe, a precision screening platform that speeds drug discovery and provides risk assessment; a proprietary automated laboratory that provides a time advantage of more than 24 months in biotherapeutic development; and an AI-driven value chain that processes the company's proprietary biological data end-to-end. BioCopy claims this integrated platform compresses cancer drug development timelines from a traditional three years to approximately 12 months.

BioCopy's business model is partnership-driven rather than product-driven. As a pre-commercial biotech, the company does not sell drugs or services directly; instead, it develops therapeutic candidates internally and seeks licensing deals, milestone payments, and co-development agreements with pharmaceutical and biotech companies for clinical development and eventual commercialization. Revenue is not yet generated, and the company is funded through venture capital and grant rounds, including a €8 million raise in March 2025 and an approximately $11.3 million round in March 2026 led by Haute Capital Partners, in addition to an earlier 2018 EISMEA grant.

Name

BioCopy

Legal name

BioCopy AG

Website

https://biocopy.de

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

BioCopy is a German-Swiss pre-clinical biotech using an AI-powered, automated platform to discover and engineer cancer biotherapeutics, advancing five pHLA-targeted antibody programs in solid and liquid tumors for partnership-based development with pharmaceutical companies.

Ownership category

akta.pro rank

Product category

Biotechnology Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)

Keywords

• AI drug discovery
• Biotherapeutics development
• Antibody engineering
• Cancer therapeutics pipeline
• PHLA-targeted antibodies

Headquarters

HQ city

Freiburg

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Infrastructure

Revenue model

1. Biopharmaceutical Development Partnerships: BioCopy develops biotherapeutics against cancer and seeks to partner with pharmaceutical companies for clinical development and commercialization. Revenue would likely come from licensing deals, milestone payments, and potential co-development agreements.
2. Drug Discovery Platform Services: The company uses its AI-assisted platform to accelerate cancer drug development from years to months, which could be offered as services to pharmaceutical partners.

Go-to-market motion1 record

Marketing channels3 records

Core offering

BioCopy develops next-generation pHLA-targeted antibody therapeutics for solid and liquid tumors using an AI-powered, end-to-end automated platform. The platform combines precision screening (ValidaTe), an automated laboratory, and an AI-driven value chain built on proprietary data to compress cancer drug development timelines from approximately three years to twelve months. The company advances five internal antibody programs and seeks pharmaceutical partners for clinical development and commercialization.

Product overview

BioCopy offers a unified AI-powered platform for biotherapeutic drug discovery and development, centered on its ValidaTe precision screening technology and proprietary automated laboratory. The platform integrates AI-driven screening, automated antibody engineering, and risk assessment into a seamless end-to-end workflow designed to reduce cancer drug development timelines from three years to approximately 12 months. The company is advancing five pHLA-targeted antibody programs across solid and liquid tumors.

Differentiator

Problem solved

Functional benefit

Products and services

• ValidaTe Precision Screening Precision screening platform that accelerates drug discovery and provides extensive risk assessment for further development of biotherapeutics, used by BioCopy's internal pipeline and offered to pharmaceutical partners.
• Automated Lab End-to-end automated laboratory platform that delivers a time advantage of more than 24 months in the discovery and development of complex biotherapeutics; the operational backbone of BioCopy's R&D.
• pHLA-Targeted Antibody Pipeline Five pHLA-targeted antibody programs in solid and liquid tumors that target cancer cells with high specificity and are intended for partnering with pharmaceutical companies for clinical development and commercialization.

Quantifiable outcome

• Reduces cancer drug development timeline from 3 years to 12 months
• +2 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Scale indicators4 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• BigHat Biosciences: AI-driven antibody engineering platform combining wet-lab high-throughput experimentation with machine learning. Direct competitor to BioCopy in AI-powered biotherapeutic discovery, with similar focus on accelerating antibody development timelines for cancer and other indications.
• Absci: AI generative biology platform for antibody and protein design, combining zero-shot generative AI models with proprietary wet-lab validation. Highly comparable to BioCopy in target customer (pharma), technology stack (AI + automated lab), and product category (de novo biologics).
• Generate Biomedicines: Generative AI biology platform creating novel protein therapeutics, including antibodies, enzymes, and peptides. Comparable to BioCopy in using AI to design programmable biologics with emphasis on automation and pharma partnership model.
• Adagene: Clinical-stage biotechnology company leveraging AI-powered antibody discovery (POWERbody, SAFEbody platforms) to develop precision cancer therapeutics. Comparable to BioCopy in oncology focus and AI-driven antibody platform approach, though more clinically advanced.
• Insilico Medicine: AI-driven drug discovery company with end-to-end platform spanning target identification, molecule design, and clinical development. Comparable to BioCopy in using AI to compress drug development timelines and pursue cancer therapeutics, though broader in scope across small molecules and biologics.
• Cradle Bio: AI protein engineering platform that uses machine learning to design and optimize proteins for biotech and pharma partners. Highly comparable to BioCopy in combining AI models with wet-lab validation for protein-based therapeutic development.

Broad incumbents

• Recursion Pharmaceuticals: Clinical-stage AI-driven biotech combining high-throughput wet-lab automation with machine learning for drug discovery across multiple therapeutic areas. Comparable to BioCopy in AI + automation thesis but operates at significantly larger scale and with broader therapeutic scope.
• Schrödinger: Computational chemistry and biology platform combining physics-based simulation with AI/ML for drug discovery. Comparable to BioCopy in pharma-platform business model and AI-driven approach, though more established and primarily focused on small molecules with biologics expansion.
• Exscientia: AI-driven precision medicine company with end-to-end drug discovery platform, primarily in small molecules but expanding into biologics. Comparable to BioCopy in AI-platform business model and pharma partnership approach, with broader therapeutic scope and more clinical-stage assets.
• Isomorphic Labs: Alphabet-backed AI drug discovery company leveraging DeepMind's AlphaFold and related technologies for structure-based drug design. Comparable to BioCopy in AI-first drug discovery approach and pharma partnership model, though with substantially greater capital resources and broader therapeutic ambitions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/biocopy
• Xx.com/biocopygmbh

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioCopy